Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P538: Enteral nutrition for the maintenance of remission in adults with inactive Crohn’s disease: A meta-analysisECCO '18 Vienna
Year: 2018
Authors:

W. Tang*

The Second Affiliated Hospital of Soochow University, Gastroenterology, Suzhou, China

P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

G. Konijeti1,2, B. Molparia2,3, E. Akhtar*, X. Wang2, J. Chang4, J. Lewis5, A. Chandrasekaran6, S. Groven7, G. Oliveira2, A. Torkamani2,3

1Scripps Clinic, Division of Gastroenterology, La Jolla, USA, 2The Scripps Research Institute, Scripps Translational Science Institute, La Jolla, USA, 3The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA, 4University of California, San Diego, Division of Gastroenterology, La Jolla, USA, 5University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, USA, 6Scripps Clinic, Department of Internal Medicine, La Jolla, USA, 7San Diego State University, School of Exercise and Nutritional Sciences, San Diego, USA

P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centreECCO '18 Vienna
Year: 2018
Authors:

N. Mezzina1*, A. Cassinotti1, S. Carmagnola1, A. Massari1, S. Grillo2, S. Landi2, G. Maconi1, S. Ardizzone1

1ASST Fatebenefratelli Sacco, DIBIC “L. Sacco” University of Milan, Gastrointestinal Unit, Milan, Italy, 2University Hospital of Parma, Department of Gastroenterology and Digestive Endoscopy, Parma, Italy

P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)ECCO '18 Vienna
Year: 2018
Authors:

T. Hisamatsu1*, T. Matsumoto2, K. Watanabe3, H. Nakase4, S. Motoya5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe17, T. Hibi18, DIAMOND study group1

1Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan, 2Iwate Medical University School of Medicine, Division of Gastroenterology, Department of Medicine, Morioka, Japan, 3Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 4Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, 5Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, 6Tokyo Yamate Medical Center, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, 7Ishida Clinic of IBD and Gastroenterology, Oita, Japan, 8Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, 9Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan, 10Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 11Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, 14Keio University School of Medicine, Department of Internal Medicine, Tokyo, Japan, 15Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 16The Institute of Medical Science Hospital, The University of Tokyo, Center for Translational Research, Tokyo, Japan, 17Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 18Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

P542: Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysisECCO '18 Vienna
Year: 2018
Authors:

M.C. Choy1,2,3*, D. Seah1, D.M. Faleck4, S.C. Shah4, A. Al-Khoury5, Y.-K. An6, G. Radford-Smith6, T. Bessissow5, A.C. Ford7,8, M. Dubinksy4, N. Yeomans2, P. De Cruz1,2

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2University of Melbourne, Austin Academic Centre, Melbourne, Australia, 3St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia, 4Mount Sinai, Icahn School of Medicine, New York, USA, 5McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, 6Royal Brisbane and Women's Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia, 7Leeds Teaching Hospitals NHS Trust, Gastroenterology Institute, Leeds, UK, 8University of Leeds, Leeds Institute of Biomedical and Clinical Sciences, Leeds, UK

P543: Higher post-induction infliximab serum trough levels are associated with healing of fistulising perianal Crohn’s disease in childrenECCO '18 Vienna
Year: 2018
Authors:

W. El-Matary1*, T. Walters2, H. Huynh3, J. deBruyn4, D. Mack5, K. Jacobson6, M. Sherlock7, P. Church2, E. Wine3, M. Carroll3, E. Benchimol5, S. Lawrence6, A. Griffiths2

1University of Manitoba, Pediatrics, Winnipeg, Canada, 2Hospital for Sick Children, University of Toronto, Department of Paediatrics; Department of Gastroenterology, Hepatology and Nutrition, Toronto, Canada, 3University of Alberta, Department of Pediatrics, Edmonton, Canada, 4Pediatrics, University of Calgary, Calgary, Canada, 5University of Ottawa, Department of Pediatrics, Ottawa, Canada, 6BC Children's Hospital, Vancouver, Canada, 7McMaster University, Department of Pediatrics, Hamilton, Canada

P544: Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE studyECCO '18 Vienna
Year: 2018
Authors:

B.G. Feagan1*, W.J. Sandborn2, G. D'Haens3, R.K. Pai4, S.B. Hanauer5, D.C. Wolf6, S. Vermeire7, S. Ghosh8, B.G. Levesque9, K. Shan9, R. Aranda9, W.J. Liu9, A. Olson9

1Robarts Clinical Trials, Western University, Ontario, Canada, 2University of California - San Diego, San Diego, USA, 3Academic Medical Center, Amsterdam, The Netherlands, 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, USA, 5Northwestern University Feinberg School of Medicine, Chicago, USA, 6Atlanta Gastroenterology Associates, Atlanta, USA, 7University of Leuven, Leuven, Belgium, 8University of Calgary, Calgary, Canada, 9Receptos, a Wholly Owned Subsidiary of Celgene, San Diego, USA

P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognitionECCO '18 Vienna
Year: 2018
Authors:

J. Goncalves1*, M. Santos1, R. Acurcio1, I. Iria1, L. Gouveia1, P. Brito1, A.C. Cunha Santos1, A. Barbas2,3, J. Galvão2, I. Barbosa2, F. Aires da Silva4, A. Alcobia5, M. Cavaco6, M. Cardoso1, J. Delgado Alves7,8, J. Carey9, T. Dorner10, J. Eurico Fonseca6,11, C. Palmela12, J. Torres12, C. Lima Vieira13, D. Trabuco13, G. Fiorino14, A. Strik15, M. Yavzori16, I. Rosa17, L. Correia18, F. Magro19, G. D'Haens15, S. Ben-Horin16, P. Lakatos20,21, S. Danese14

1Faculdade Farmacia Universidade Lisboa, iMed - Research Institute for Medicines, Lisboa, Portugal, 2iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal, 3Bayer Portugal, Carnaxide, Portugal, 4Centro Interdisciplinar de Investigação em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon, Lisboa, Portugal, 5Hospital Garcia de Orta (HGO), Almada, Portugal, 6Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 7CEDOC/NOVA Medical School, Lisbon, Portugal, 8Immunomediated Systemic Diseases Unit (UDIMS), Fernando Fonseca Hospital, Amadora, Portugal, 9Galway University Hospitals, Department of Rheumatology, Galway, Ireland, 10Charite Universitaetsmedizin Berlin, Department Medicine Rheumatology and Clinical Immunology, Berlin, Germany, 11Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Rheumatology Department, Lisboa, Portugal, 12Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal, 13Unidade de Gastroenterologia of CHBM, Barreiro, Portugal, 14Humanitas University; Humanitas Clinical and Research Centre, Department of Biomedical Sciences, Milan, Italy, 15Academic Medical Center, Amsterdam, The Netherlands, 16Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University, Department of Gastroenterology, Tel-Aviv, Israel, 17Portuguese Institute of Oncology of Lisbon Francisco Gentil, EPE, Lisboa, Portugal, 18Hospital de Santa Maria, Department of Gastroenterology and Hepatology, Lisboa, Portugal, 19Faculty of Medicine, University of Porto, Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal, 20Semmelweis University, First Department of Medicine, Budapest, Hungary, 21McGill University, MUHC, Montreal General Hospital, Division of Gastroenterology, Montreal, Canada

P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim resultsECCO '18 Vienna
Year: 2018
Authors:

B. Bressler1*, A.-J. Greenup1, M. Bassel2, D. Stein3, M. Soni3, G. Radulescu4, C. Neish4, J.M. Khalid5, D. Demuth5

1St. Paul's Hospital, Vancouver, Canada, 2Evidera, St-Laurent, Canada, 3Evidera, London, UK, 4Takeda, Oakville, Canada, 5Takeda Development Centre Europe Ltd., London, UK

P547: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)ECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, S. Rundquist1*, V. Lykiardopoulos2, P. Karlén3, O. Grip4, C. Söderman5, S. Almer6, E. Hertervig7, J. Gunnarsson8, C. Malmgren9, J. Delin10, H. Strid11, M. Sjöberg12, D. Öberg13, D. Bergemalm1, R. Udumyan14, H. Hjortswang2, The SWIBREG SVEAH Study Group, J. Halfvarson1

1Faculty of Medicine and Health, Örebro University, Department of Gastroenterology, Örebro, Sweden, 2Linköping University, Department of Gastroenterology, Linköping, Sweden, 3Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden, 4Skåne University Hospital, Department of Gastroenterology, Malmö, Sweden, 5St Göran Hospital, Department of Internal Medicine, Stockholm, Sweden, 6Karolinska Institute, Department of Medicine, Stockholm, Sweden, 7Skåne University Hospital, Department of Gastroenterology, Lund, Sweden, 8Kungsbacka Hospital, Department of Internal Medicine, Kungsbacka, Sweden, 9Takeda Pharma AB, Solna, Sweden, 10Ersta Hospital, Department of Gastroenterology, Stockholm, Sweden, 11Södra Älvsborgs Hospital, Department of Internal Medicine, Borås, Sweden, 12Skaraborgs Hospital, Department of Internal Medicine, Lidköping, Sweden, 13Sunderby Hospital, Department of Internal Medicine, Sunderbyn, Sweden, 14Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden

P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M. Ferrante*, B. Verstockt, L. Gijbels, G. Van Assche, S. Vermeire

University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experienceECCO '18 Vienna
Year: 2018
Authors:

F.S. Macaluso1*, S. Compagnoni1, S. Renna1, S. Maisano1, A. Casà1, G. Solina2, A.G. Rizzo3, F. La Seta4, M. Ventimiglia1, A. Orlando1, M. Cottone1

1Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy, 2Unit of Surgery, “Villa Sofia-Cervello” Hospital, Palermo, Italy, 3Unit of Pathology, Villa Sofia-Cervello'' Hospital, Palermo, Italy, 4Radiology Unit, “Villa Sofia-Cervello” Hospital, Palermo, Italy

P550: Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
Year: 2018
Authors:

J. Halasz1*, C. Lu1, G. Kaplan1,2, D. Tanyingoh2, C. Seow1, R. Panaccione1, S. Devlin1, S. Wilson3, K. Novak1

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Community Health Sciences, Calgary, Canada, 3University of Calgary, Foothills Medical Centre, Diagnostic Imaging, Calgary, Canada

P551: 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international studyECCO '18 Vienna
Year: 2018
Authors:

R. Mao1, J. Guo1, R. Luber2, B.-l. Chen1, Y. He1, Z.-r. Zeng1, S. Ben-Horin3, M. Sparrow2, R. Xavier4, M.-h. Chen1*

1First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2The Alfred Hospital, Melbourne, Australia, 3Sheba Medical Center, Tel-aviv, Israel, 4University Hospital of Saint Etienne, Saint Etienne, France

P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisationECCO '18 Vienna
Year: 2018
Authors:

H. Patel1*, J.M. Khalid1, S. Shah2, R. Shah3, A. Berger2

1Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 2Evidera, Real World Evidence, Waltham, MA, USA, 3Evidera, Real World Evidence, London, UK

P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumabECCO '18 Vienna
Year: 2018
Authors:

C. Berger1*, A. Pilch1, J. Ruppert1, F.-P. Armbruster1, J. Stein2,3, K. Farrag2,3

1Immundiagnostik AG, Bensheim, Germany, 2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 3DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximabECCO '18 Vienna
Year: 2018
Authors:

R. Palaparthy1*, S. Schmitt2, M.I. Rehman3, C.-H. Cai1, K. Wang1, O. von Richter2

1Pfizer Inc., Biosimilars Development, New York, USA, 2Global Clinical Development, Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, Germany, 3Pfizer Inc., Andover, USA

P555: Coagulation disorders in a population of patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Pinho1*, F. Pires1, D. Martins1, P. Sousa1, E. Cancela1, M. Farinha2, A. Silva1, P. Ministro1

1Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal, 2Centro Hospitalar Tondela-Viseu, Pathology, Viseu, Portugal

P556: Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short-and long-term outcomesECCO '18 Vienna
Year: 2018
Authors:

A. Hammami*, B. Hasnaoui, S. Hachicha, M. Ksiaa, H. Jaziri, N. Elleuch, A. Brahem, S. Ajmi, A. Ben Slama, A. Jmaa

Hospital University of Sahloul, Gastroenterology, Sousse, Tunisia

P557: Cost-effectiveness of infliximab vs. surgery for severe chronic ulcerative colitis: a Markov analysisECCO '18 Vienna
Year: 2018
Authors:

S. Holubar1*, P. Dulai2, B. Piazik3, S. Finlayson4, B. Udeh5

1Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, USA, 2University of California San Diego, Medicine, San Diego, USA, 3Elliot Health Systems, Manchester, USA, 4University of Utah, Surgery, Salt Lake City, USA, 5Cleveland Clinic, Clinical Transformation, Cleveland, USA